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96 Abstract Pituitary adenylate cyclase activating polypeptide (PACAP) is an
endogenous neuropeptide having a widespread distribution both in
the nervous system and peripheral organs including the female
reproductive system. Both the peptide and its receptors have been
shown in the placenta but its role in placental growth, especially its
human aspects, remains unknown. The aim of the present study was
to investigate the effects of PACAP on invasion, proliferation, cell
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survival, and angiogenesis of trophoblast cells. Furthermore,
cytokine production was investigated in human decidual and
peripheral blood mononuclear cells. For in vitro studies, human
invasive proliferative extravil lous cytotrophoblast (HIPEC) cells and
HTR-8/SVneo human trophoblast cells were used. Both cell types
were used for testing the effects of PACAP on invasion and cell
survival in order to investigate whether the effects of PACAP in
trophoblasts depend on the examined cell type. Invasion was
studied by standardized invasion assay. PACAP increased
proliferation in HIPEC cells, but not in HTR-8 cells. Cell viabil ity
was examined using MTT test, WST-1 assay, and annexin
V/propidium iodide flow cytometry assay. Survival of HTR-8/SVneo
cells was studied under oxidative stress conditions induced by
hydrogen peroxide. PACAP as pretreatment, but not as
co-treatment, significantly increased the number of surviving HTR-8
cells. Viabil ity of HIPEC cells was investigated using methotrexate
(MTX) toxicity, but PACAP1-38 could not counteract its toxic effect.
Angiogenic molecules were determined both in the supernatant
and the cell lysate by angiogenesis array. In the supernatant, we
found that PACAP decreased the secretion of various angiogenic
markers, such as angiopoietin, angiogenin, activin, endoglin,
ADAMTS-1, and VEGF. For the cytokine assay, human decidual
and peripheral blood lymphocytes were separated and treated with
PACAP1-38. Th1 and Th2 cytokines were analyzed with CBA assay
and the results showed that there were no significant differences in
control and PACAP-treated cells. In summary, PACAP seems to
play various roles in human trophoblast cells, depending on the
cell type and microenvironmental influences.
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14 Abstract Pituitary adenylate cyclase activating polypeptide
15 (PACAP) is an endogenous neuropeptide having a widespread
16 distribution both in the nervous system and peripheral organs
17 including the female reproductive system. Both the peptide
18 and its receptors have been shown in the placenta but its role
19 in placental growth, especially its human aspects, remains
20 unknown. The aim of the present study was to investigate
21 the effects of PACAP on invasion, proliferation, cell survival,
22 and angiogenesis of trophoblast cells. Furthermore, cytokine
23 production was investigated in human decidual and peripheral
24 blood mononuclear cells. For in vitro studies, human invasive
25 proliferative extravillous cytotrophoblast (HIPEC) cells and
26 HTR-8/SVneo human trophoblast cells were used. Both cell
27 types were used for testing the effects of PACAP on invasion
28 and cell survival in order to investigate whether the effects of
29 PACAP in trophoblasts depend on the examined cell type.
30 Invasion was studied by standardized invasion assay. PACAP
31 increased proliferation in HIPEC cells, but not in HTR-8 cells.
32 Cell viability was examined using MTT test, WST-1 assay,
33 and annexin V/propidium iodide flow cytometry assay.
34 Survival of HTR-8/SVneo cells was studied under oxidative
35stress conditions induced by hydrogen peroxide. PACAP as
36pretreatment, but not as co-treatment, significantly increased
37the number of surviving HTR-8 cells. Viability of HIPEC cells
38was investigated using methotrexate (MTX) toxicity, but
39PACAP1-38 could not counteract its toxic effect.
40Angiogenic molecules were determined both in the superna-
41tant and the cell lysate by angiogenesis array. In the superna-
42tant, we found that PACAP decreased the secretion of various
43angiogenicmarkers, such as angiopoietin, angiogenin, activin,
44endoglin, ADAMTS-1, and VEGF. For the cytokine assay,
45human decidual and peripheral blood lymphocytes were sep-
46arated and treated with PACAP1-38. Th1 and Th2 cytokines
47were analyzed with CBA assay and the results showed that
48there were no significant differences in control and PACAP-
49treated cells. In summary, PACAP seems to play various roles
50in human trophoblast cells, depending on the cell type and
51microenvironmental influences.
52Keywords Trophoblast . Invasion . Proliferation . Decidua .
53Lymphocyte . Angiogenesis
54Introduction
55Pituitary adenylate cyclase activating polypeptide (PACAP)
56belongs to the vasoactive intestinal peptide (VIP)/secretin/
57glucagon peptide family. It was first isolated as a hypothalam-
58ic peptide based on its effect to influence adenylate cyclase
59activity in the pituitary gland (Miyata et al. 1989). PACAP is
60widely distributed throughout the entire body including fe-
61male reproductive organs (Steenstrup et al. 1995; Ko et al.
621999; Reglodi et al. 2012b; Koves et al. 2014; Csanaky et al.
632014). It occurs in two forms, PACAP1-27 and PACAP1-38,
64with PACAP1-38 being the predominant form in mammals.
65PACAP exerts its effect through class II G-protein-coupled
66receptors. The specific PACAP receptor is called PAC1,
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67 which binds VIP with much less affinity, while VPAC1 and
68 VPAC2 receptors have similar high affinity for VIP and
69 PACAP (Laburthe and Couvineau 2002; Laburthe et al.
70 2007; Lutz et al. 1999; Muller et al. 2007; Vaudry et al.
71 2009). Both PACAP1-38 and PACAP1-27, as well as their
72 receptors have been found in the human pregnant uterus and
73 placenta (Koh et al. 2005; Scaldaferri et al. 2000). PACAP has
74 been shown to cause a concentration-dependent relaxation on
75 stem villi and intramyometrial arteries, suggesting a
76 vasoregulatory role in the uteroplacental unit (Steenstrup
77 et al. 1996). PACAP has been suggested to play a role in
78 decidualization, and the time-related localization of
79 endometrial-uterine PACAP has been implicated in facilita-
80 tion of endometrial blood flow (Spencer et al. 2001a, b).
81 PACAP knockout mice have decreased fertility, described in
82 numerous studies (Reglodi et al. 2012a). This is in part due to
83 impaired implantation (Q2 Isaac and Sherwood 2008; Koh et al.
84 2003) in addition to other deficiencies described in mice
85 lacking endogenous PACAP (Reglodi et al. 2012a).
86 Previously, we have investigated the levels of both
87 PACAP isoforms in first trimester and full-term human
88 placentas (Brubel et al. 2010). Both PACAP1-38 and
89 PACAP1-27 could be detected in different parts of the
90 full-term human placenta. Increasing PACAP1-38 content
91 was measured in the placenta during pregnancy, both on
92 the maternal and the fetal side. PACAP has been shown to
93 influence cell survival of various cell types against harmful
94 stimuli. In most experiments, PACAP enhances cell surviv-
95 al (Vaudry et al. 2009; Reglodi et al. 2011; Racz et al.
96 2010; Horvath et al. 2010; Fabian et al. 2012). However,
97 investigating the effect of PACAP on survival of different
98 cell types, cell survival-decreasing effect or no effect could
99 also be detected depending on the examined cell type,
100 PACAP concentrations, and other factors present (Li et al.
101 2006; Wojcieszak and Zawilska 2014; D’Amico et al.
102 2013;Q3 Horvath et al. 2011). Based on this background, it
103 can be expected that PACAP has an effect on trophoblast
104 cells of other origins and on placental growth. In our
105 previous experiments, PACAP enhanced the survival-
106 decreasing effect of H2O2-induced oxidative stress in JAR
107 human choriocarcinoma cells (Q4 Boronkai et al. 2009). The
108 first aim of our study was to examine whether the effect of
109 PACAP in trophoblast cells depends on the type of the
110 cells. Therefore, we tested the effect of PACAP on cell
111 viability of HTR-8/Svneo, nontumorous primary trophoblast
112 cells. Trophoblast cells, with their invasive capability, play
113 a pivotal role during the implantation of blastocyst in the
114 early phase of gestation. Therefore, the second aim of the
115 present study was to investigate whether PACAP influences
116 the invasiveness and angiogenesis of human trophoblast
117 cells. Moreover, we examined the effect of PACAP on
118 decidual lymphocytes and compared it with that of periph-
119 eral blood mononuclear cells. The common goal of our
120experiments was to examine whether there is a relationship
121between PACAP and different cell types related to human
122pregnancy.
123Materials and Methods
124Cell Lines
125HTR-8/SVneo Cells
126Human extravillous trophoblast-derived cell line HTR-8/
127SVneo was a generous gift of Charles Graham (Department
128of Anatomy and Cell biology, Queen’s University, Kingston,
129ON, Canada L7L 3 N6). HTR-8/SVneo cells were cultured in
130RPMI (Invitrogen Life Technologies, Carlsbad, CA, USA)
131supplemented with 10 % fetal bovine serum (PAA, Csertex
132Kft. Hungary).
133HIPEC 65
134Human invasive, proliferative extravillous cytotrophoblast
135cell line (HIPEC) 65 was a generous gift from Pr. D Evain-
136Brion, Paris. These primary cells were transformed with sim-
137ian virus 40 large T antigen for studying cell invasion (Pavan
138et al. 2003). HIPEC 65 cells were cultured in DMEM high
139glucose/Ham F-12 (1/1) supplemented with 10 % fetal bovine
140serum (FBS, Biochrom AG (Oxoid AG, Basel, Switzerland))
141and antibiotic mixture (100 U/ml penicillin, 100 μg/ml strep-
142tomycin) (Invitrogen, Basel, Switzerland) at 37 °C in a hu-
143midified, 5 % CO2 atmosphere.
144Experiments with HTR-8/SVneo Cells
145Cell Viability
146HTR-8/SVneo cells were plated on 96-well microplate at a
147density of 3×104 per well. To investigate the effect of PACAP,
148PACAP1-38 was added either simultaneously or prior to
149oxidative stress evoking H2O2. Cells were assigned to one of
150the experimental groups: (1) control group of cells (no treat-
151ment); (2) and (3) cells exposed to 10 or 100 nM PACAP1-38
152alone simultaneously or 2 h before starting the H2O2 treat-
153ment; (4) cells treated with 150 μMH2O2 for 24 h; (5) and (6)
154cells either cotreated with 10 or 100 nM PACAP1-38 and
155150 μM H2O2 for 24 h or pretreated with 10 or 100 nM
156PACAP1-38 for 2 h then with 150 μM H2O2 for 24 h.
157Following the treatments, viability of the HTR-8/SVneo
158cells was determined by colorimetric MTT assay (3-(4,5-di-
159methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide,
160Sigma, Hungary), based on the reduction of MTT into a blue
161formazan dye by viable mitochondria. At the end of the
162treatments, cells were washed twice with phosphate-buffered
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163 saline (PBS, Sigma), then incubated with PBS containing
164 0.5 mg/ml of MTT for 3 h at 37 °C in an atmosphere of 5 %
165 CO2. The solution was aspirated carefully and 200 μl of
166 dimethylsulfoxide (Sigma, Hungary) was added to dissolve
167 the blue-colored formazan particles and absorbance was mea-
168 sured by an ELISA reader (Dialab Kft., Hungary) at 570 nm
169 representing the values in arbitrary unit (AU).
170 Invasion Assay of HTR-8/SVneo Cells
171 The invasiveness of HTR-8/SVneo cells was assessed
172 by using Oris™ Cell Invasion and Detection Assay
173 (Platypus Technologies, Madison, WI, USA) according
174 to the manufacturer’s instructions. Briefly, 96-well plates
175 were coated with basement membrane extract (BME,
176 3 mg/ml) and wells were populated with Cell Seeding
177 Stoppers to restrict cell seeding to the outer annular
178 regions; then seeded with 75,000 cells. Stoppers were
179 removed after 24 h, resulting in an unseeded region in
180 the center of each well (i.e., the detection zone). Cells
181 were overlaid with 10 mg/ml BME containing 15 %
182 FBS, then media with or without 1 μM PACAP1-38
183 was added to the wells. After 72 h, cells were labeled
184 with calcein AM and the detection zone was analyzed
185 by an Olympus Fluoview FV-1000 confocal microscope.
186 Cell invasion was analyzed by measuring the area of the
187 detection zones using ImageJ analysis software. Invasion
188 was determined by area closure which was calculated as
189 follows: invaded area of detection zone/full area of
190 detection zone×100.
191 Angiogenesis Array
192 HTR-8/SVneo cells were treated with 1 μM PACAP1-38 for
193 24 h. Supernatants of PACAP1-38 treated or untreated HTR-
194 8/SVneo cells were analyzed by Human Angiogenesis Array
195 (R&D Systems, Biomedica Hungaria, Budapest, Hungary).
196 This array is based on binding between sample proteins and
197 carefully selected captured antibodies spotted on nitrocellu-
198 lose membranes. The supernatants were collected as described
199 by the manufacturer. The kit contains all buffers, detection
200 antibodies, and membranes necessary for the measurements.
201 The array was performed as described by the manufacturer.
202 Briefly, after blocking the array membranes for 1 h and adding
203 the reconstituted detection antibody cocktail for another 1 h at
204 room temperature, the membranes were incubated with 1 ml
205 of cellular extracts or 500 μl supernatant at 2–8 °C overnight
206 on a rocking platform. After washing with buffer three times
207 and adding of horseradish peroxidase-conjugated streptavidin
208 to each membrane, we exposed them to a chemiluminescent
209 detection reagent. Array data on developed X-ray film were
210 quantitated by ImageJ software.
211Experiments with HIPEC 65 Cells
212Cell Viability Tests
213HIPEC 65 cells were seeded into 96-well plates at a density of
214104 cell/well and cultured in medium overnight before the
215experiment. HIPEC cells were randomly assigned to one of
216the four experimental groups: (1) control group of cells, (2)
217100 nM PACAP1-38, (3) 10 μM MTX, and (4) pretreatment
218with 100 nM PACAP1-38 followed by 10 μM MTX.
219After 48 h of treatment, viability of HIPEC cells was
220determined by colorimetric WST-1 assay. The medium was
221removed, and fresh DMEM/FCS containing 0.5 % of the
222water-soluble WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-
2235-(2,4-disulfophenyl)-2H-tetrazolium) solution was added.
224Cells were then incubated for 3 h at 37 °C in an atmosphere
225of 5 % CO2. After 3 h of incubation, optical densities were
226determined by an ELISA reader (Anthos Labtech 2010;
227Vienna, Austria) at the wavelength of 550 nm representing
228the values in AU. All experiments were run in four parallels
229and repeated six times. Results are expressed as percentage of
230control values.
231Cell viability was also investigated by annexin V–
232propidium iodide staining. By conjugating a fluorescent group
233to annexin V, apoptosis can be quantitatively detected using
234flow cytometry. The ratio of apoptosis was evaluated after
235double staining with fluorescein isothiocyanate (FITC)-la-
236beled annexin V and propidium iodide (Soft Flow, Hungary)
237using flow cytometry, as described previously (Gasz et al.
2382006). First, the medium was discarded and wells were
239washed twice with isotonic sodium chloride solution. Cells
240were removed from plates using a mixture of 0.25 % trypsin
241(Sigma, Hungary), 0.2 % ethylene-diamin tetra-acetate
242(EDTA; Sigma, Hungary), 0.296 % sodium citrate, and
2430.6 % sodium chloride in distillated water. This medium was
244applied for 15 min at 37 °C. Removed cells were washed
245twice in cold PBS and were resuspended in binding buffer
246containing 10mMHEPESNaOH, pH 7.4, 140mMNaCl, and
2472.5 mM CaCl2. Cell count was determined in Burker’s cham-
248ber for achieving a dilution in which 1 ml of solution contains
249106 cells. One hundred microliters of cell suspension (105
250cells) was transferred into 5 ml round-bottom polystyrene
251tubes. Cells were incubated for 15 min with FITC-
252conjugated annexin V molecules and propidium iodide (PI).
253After this period of incubation, 400 μl of annexin-binding
254buffer (BD Biosciences, USA) was added to the tubes as
255described by the manufacturers. The samples were immedi-
256ately measured by BD FacsCalibur flow cytometer (BD
257Biosciences, USA). Results were analyzed by Cellquest soft-
258ware (BD Biosciences, USA). Quadrant dot plot was intro-
259duced to identify living and necrotic cells and cells in early or
260late phase of apoptosis. Necrotic cells were identified as single
261PI-positive. Apoptotic cells were branded as annexin V-FITC-
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262 positive only and cells in late apoptosis were recognized as
263 double-positive for annexin V-FITC and PI. Cells in each
264 category were expressed as percentage of the total number
265 of stained cells counted.
266 Invasion and Proliferation Assay
267 Cell invasion assay was performed in an invasion chamber
268 based on the Boyden chamber principle. Each chamber con-
269 tains an insert fitted with an 8 μM pore size polycarbonate
270 membrane precoated with rat tail collagen I (5 μg/cm2). The
271 inserts were washed in DMEM and incubated for 30 min at
272 room temperature. Each insert was filled with 5×105 cells in
273 400 μl of serum-free media. The following experimental
274 groups were used: (1) cells with no treatment and (2) cells
275 exposed to 100 nM PACAP1-38. Cells were incubated for
276 72 h at 37 °C in a CO2 (5 %) incubator. After incubation,
277 supernatant was discarded and viable cells invaded the colla-
278 gen were stained with 400 μl of crystal violet for 20 min at
279 room temperature. After washing, non-invading cells were
280 removed from the insert. Each stained insert was transferred
281 in a new chamber containing 200 μl of a solution of H2O/
282 ethanol/acetic acid (49:50:1) for 20 min at room temperature.
283 One hundred microliters of the dye mixture was transferred to
284 a 96-well microtiter plate for colorimetric measurement.
285 Absorbance proportional to cell concentration was determined
286 at 560 nm.
287 Proliferation assay was performed on cells found in the
288 chambers simultaneously with invasion assay at the end of
289 72-h incubation. After removal of medium, 400 μl serum-free
290 medium containing 20 % of CellTiter 96 Aqueous One solu-
291 tion reagent was added to the cells. This plate was incubated
292 for 3 h at 37 °C in a humified, 5 % CO2 atmosphere. After
293 incubation, 100 μl of the medium of each well was transferred
294 in a 96-well plate and absorbance proportional to cell concen-
295 tration was determined at 560 nm using colorimetric test.
296
297 Experiments with Decidual and Peripheral Blood
298 Mononuclear Cells of Healthy Pregnant Women
299 Patients and Human Samples
300 All subjects were patients of the Department of Obstetrics and
301 Gynecology at the University of Pecs. Samples of decidual
302 tissues and matched peripheral blood were obtained from nine
303 healthy pregnant women underwent elective termination of
304 apparently normal pregnancies at the 6–10 weeks of gestation.
305 They did not have a history of spontaneous abortion, ectopic
306 pregnancy, preterm delivery, or stillbirth.
307 Written informed consent was obtained from all partici-
308 pants. The study protocol conforms to the ethical guidelines of
309the 1975 Declaration of Helsinki as reflected in a priori
310approval by the Regional Ethical Committee at the Faculty
311of Medicine, University of Pecs.
312Isolation of Decidual Mononuclear Cells
313Isolation of decidual mononuclear cells (DMC) from decidual
314tissue was performed as previously described (Szereday et al.
3152012). Briefly, decidual tissue was cut into pieces, exposed to
316collagenase IV digestion (equal volume of tissue and 0.5 %
317collagenase type IV, Sigma-Aldrich Kft., Hungary) at 37 °C
318for 60 min with gentle stirring on the magnetic stirrer. Cell
319suspension was passed through 100 μm nylon mesh (BD
320Biosciences, USA) for tissue debris elimination and centri-
321fuged at 600×g for 10 min. The pellet was resuspended and
322was passed through 70 μm nylon mesh (BD Biosciences,
323USA). The pellet was resuspended again in RPMI 1640
324(Csertex Kft., Hungary) and overlaid on Ficoll-Paque gradient
325and centrifuged at 800×g for 20 min. DMC were collected
326from the interface, washed, and passed through 40 μm mesh
327(BD Biosciences) and resuspended 106/ml of cell culture
328medium [RPMI 1640 supplemented with L-glutamine
329(2 mM), penicillin (1×10−5 U/l), streptomycin sulfate
330(0.05 g/l), and 10 % fetal calf serum (all from GIBCO, Life
331Technologies, Hungary)].
332Isolation of Decidual Lymphocytes
333Isolated decidual lymphocytes (DL) were obtained as non-
334adherent cell fraction of DMC cultured on 100 mm×20 mm
335tissue culture Petri dish in humidified 5 % CO2 incubator at
33637 °C, after the long adherence procedure (24 h).
337Isolation of Peripheral Blood Mononuclear Cells
338Ten milliliters of venous blood was taken. Peripheral blood
339mononuclear cells (PBMC) were separated from heparinized
340venous blood on Ficoll-Paque gradient. Separated peripheral
341blood lymphocytes were obtained as non-adherent cell frac-
342tion of PBMC cultured on 100 mm×20 mm tissue culture
343Petri dish in humidified 5 % CO2 incubator at 37 °C, after the
344long adherence procedure (24 h).
345Cytometric Bead Array (CBA)
346Concentration of cytokines from supernatants was determined
347using a human Th1/Th2 CBA kit (BD Biosciences, USA)
348which allowed for the simultaneous detection of IL-2, IL-4,
349IL-6, IL-10, TNF-α, and IFN-γ. Aliquoted samples were
350thawed and CBA analysis performed according to the manu-
351facturer’s protocol. Briefly, beads coated with capture anti-
352bodies were mixed. Fifty microliter of the capture bead mix-
353ture was added to 50 μl of sample. To these sample-bead
J Mol Neurosci
JrnlID 12031_ArtID 337_Proof# 1 - 22/05/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
354 compounds, 50 μl of phycoerythrin conjugated detection an-
355 tibody was added and this mixture was incubated for 3 h in
356 dark at room temperature. The samples thenwere washed with
357 1 ml of wash buffer in 1,100 rpm for 5 min and the pellets
358 were resuspended in 300 μl wash buffer. Cytokine standards
359 were serially diluted to facilitate the construction of calibration
360 curves necessary for determining protein concentrations of
361 test samples. Flow cytometric analysis was performed on a
362 BD FACSCalibur (BD Immunocytometry Systems,
363 Erembodegen, Belgium) with Cell Quest software and data
364 were analyzed with FCS Express V3 software.
365 Angiogenesis Array
366 Supernatants of PACAP1-38-treated decidual and peripheral
367 blood mononuclear cells were also analyzed by angiogenesis
368 array as described above.9
370 Results
371 Experiments on HTR-8/SVneo Cells
372 Cell Viability Test
373 Viability of HTR-8/SVneo cells after H2O2 treatment was
374 measured by MTT assay (Fig. 1). Exposure to 150 μM
375 H2O2 for 24 h resulted in a significant decrease in cell viabil-
376 ity. PACAP1-38 alone had no effect on cell viability.
377 Pretreatment with 10 or 100 nMPACAP1-38 led to significant
378 increase in the ratio of living cells, with no significant differ-
379 ence between the 10 and 100 nM concentrations of PACAP1-
380 38 (Fig. 1a). In contrast to these findings, simultaneous
381 PACAP1-38 treatment showed no effect against H2O2-in-
382 duced oxidative stress (Fig. 1b).
383 Invasion Assay
384 To test the potential of PACAP on invasive behavior of HTR-
385 8/SVneo human first trimester extravillous trophoblast cells,
386 invasiveness of cells in the presence or absence of PACAP1-
387 38 was analyzed by cell invasion assay (Fig. 2a). PACAP1-38
388 treatment did not significantly alter the invasiveness of HTR-
389 8/SVneo trophoblast cells (Fig. 2b).
390 Angiogenesis Array
391 Cell-conditioned media of untreated or PACAP1-38 treated
392 HTR-8/SVneo cells were subjected to angiogenesis array
393 (Fig. 3a), suitable to measure protein levels of 51
394 angiogenesis-related molecules. Levels of several angiogenic
395 factors were markedly decreased in the cell culture superna-
396 tants after 24 h PACAP1-38 treatment. Secreted levels of
397activin A, ADAMTS-1, angiogenin, angiopoietin-1, endo-
398crine gland-derived vascular endothelial growth factor (EG-
399VEGF), and endoglin were reduced by 69, 79, 66, 91, 45, and
40055 %, respectively (Fig. 3b).
401Experiments on HIPEC65 Cells
402Cell Viability Tests
403Viability of HIPEC 65 cells after methotrexate treatment was
404measured by WST-1 assay (Fig. 4). Methotrexate treatment
405significantly decreased cell survival in HIPEC 65 cells, and
406this effect could not be altered by PACAP1-38. In order to
407distinguish apoptotic cells from necrotic and living cells,
408annexin V–propidium iodide staining was used. Similarly to
409results obtained from WST-1 assay, PACAP1-38 could not
410counteract the cell survival decreasing effect of MTX (Fig. 5).
411Invasion and Proliferation Assay
412Invasion assay performed on HIPEC 65 cells (Fig. 6) showed
413that addition of PACAP1-38 decreased the invasion of the
414HIPEC 65 cells and increased their proliferation.
415Experiments on Decidual and Peripheral Blood Mononuclear
416Cells
417Angiogenesis Array
418Cell-conditioned media of untreated and PACAP1-38 treated
419(24 h) human peripheral blood and decidual mononuclear cells
420were also analyzed by angiogenesis protein array (Fig. 7).
421PACAP1-38 did not alter the secreted levels of tested angiogenic
422molecules by peripheral blood (Fig. 7a) or decidual (Fig. 7b)
423mononuclear cells.
424We detected amphiregulin, endothelin-1, GM-CSF, IL-1β,
425IL-8, MIP-1α, matrix metalloproteinases (MMP)-8, MMP-9,
426TIMP1, CXCL4, and serpin E1 molecules in the supernatants
427of peripheral blood mononuclear cells (Fig. 7a). The decidual
428blood mononuclear cells also produced coagulation factor III,
429DPPIV, EG-VEGF, IGFBP-1, IGFBP-2, IGFBP-3, MCP1, and
430prolactin (Fig. 7b). Amphiregulin and CXCL4 were not present
431in the supernatants of decidual blood mononuclear cells
432(Fig. 7b).
433Inflammatory Cytokine Production by Decidual
434and Peripheral Blood Mononuclear Cell in Healthy Pregnant
435Women
436Th1 and Th2 cytokines were analyzed by CBA system.
437Inflammatory cytokines production by decidual and PBMC
438was not altered after PACAP1-38 or PACAP antagonist
439PACAP6-38 treatment compared to control samples (Table 1). 40
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441 Discussion
442 The common aim of our study was to use experiments exam-
443 ining the possible role of PACAP related to human pregnancy.
444In the first set of experiments, we investigated whether
445PACAP influences cell survival of primary trophoblast cell
446line exposed to H2O2-induced oxidative stress. Oxidative
447stress plays an important role in placental pathology. It was
Fig. 1 Effect of PACAP1-38 (a)
cotreatment and (b) pretreatment
on viability of HTR-8/SVneo
cells as measured by MTT assay
exposed to H2O2 for 24 h. Data
are expressed as percentage of
living cells ± SEM. **p<0.01,
***p<0.001, compared to control
values; #p<0.05 compared to the
H2O2-treated groups
Fig. 2 PACAP1-38 does not alter
invasiveness of HTR-8/SVneo
trophoblast cells. a Invasion of
untreated or 1 μM PACAP1-38
treated HTR-8/SVneo cells into
the detection zones after 72 h is
shown. Cells were labeled with
calcein AM (confocal
microscope, bar 2 mm). b
Quantification of the invasion
assay. Area closure (%) is
calculated frommeasured areas of
invasion at 72 h. Data are
presented as mean ± SEM from
three wells per condition
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448 suggested as a contributory factor in pathological events like
449 miscarriage and preeclampsia (Q6 Burton and Jauniaux 2004;
450 Poston et al. 2011). Previously PACAP has been shown to
451 decrease cell viability of JAR cells originating from human
452 choriocarcinoma (Boronkai et al. 2009). This was rather sur-
453 prising given the common survival-promoting effect of
454 PACAP in most cell types (Vaudry et al. 2009; Reglodi et al.
455 2011). Here, we tested whether this effect of PACAP on cell
456 survival depends on the malignancy of cells. We found that
457 PACAP pretreatment protected nontumorous HTR-8/SVneo
458 trophoblast cells, hence we may conclude that PACAP shows
459 different effects in malignant and nonmalignant trophoblast
460 cells. This difference has also been described in other cells, for
461 example in retinal cells, where PACAP is known to enhance
462 survival of normal retinal cells under the influence of different
463 stressors (Atlasz et al. 2010), while it reduces survival of
464 retinoblastoma cells (Wojcieszak and Zawilska 2014). Based
465 on our results, it seems that the effect of PACAP on tropho-
466 blast cells also depends on the normal versus tumorous nature
467 of the cells, on environmental influences, timing of the treat-
468 ment, and the nature of the stressor.
469We also investigated if PACAP could enhance the invasive
470ability of HTR-8/SVneo and HIPEC65 trophoblast cells. We
471observed that PACAP had detectable effects on invasion and
472proliferation of HIPEC 65 cells, but it did not affect the
473invasiveness of HTR-8/SVneo cells suggesting that its effects
474depend on the cell type. Among others, MMPs, especially
475MMP-2, are involved in the invasive process responsible for
476implantation during pregnancy ( Q7Shaun-Ram et al. 2004).
477PACAP has been shown to enhance relaxin-induced secretion
478of MMP-2 in rats (Teng et al. 2000), raising the possibility of
479its contribution to the mechanisms of implantation. The pos-
480sible explanation of its distinct effect in HTR-8/SVneo and
481HIPEC 65 cells could be the signaling mechanisms leading to
482cell death or survival and/or the presence/absence of different
483splice variants of the PACAP receptor.
484We also investigated the effects of PACAP on angiogenetic
485factors. The human placenta is principally a vascular organ
486that functions to achieve a physiological union of the maternal
487and fetal blood supplies. A major physiological role of the
488placenta is to develop an extensive vascular network allowing
489for nutrient, waste, and gas exchange between the maternal
490and fetal circulations. To accomplish this, the placenta pro-
491duces a variety of angiogenic factors. The regulation of an-
492giogenesis in pregnancy is tightly controlled. Angiogenic
493growth factors such as angiogenin, angiopoietins, endoglin,
494EG-VEGF, VEGF, and placental growth factor play an impor-
495tant role in placental vasculogenesis and angiogenesis.
496Extravillous trophoblast-derived angiogenetic factors may al-
497so play a role in spiral artery remodeling as well as control of
498trophoblast invasion. The balance between proangiogenic and
499antiangiogenic factors modulates these processes.
500Our result showed that HTR-8/SVneo cells secreted lower
501levels of activin, ADAMTS-1, angiogenin, angiopoietin-1,
502EG-VEGF, and endoglin after 24 h PACAP1-38 treatment.
Fig. 3 PACAP1-38 decreases the
secretion of several angiogenic
factors in trophoblast cells. a Cell
conditioned media of untreated or
1 μM PACAP1-38 (24 h) treated
HTR-8/SVneo cells analyzed by
protein array. b Densitometric
evaluation of the protein array.
Data are presented as mean ±
SEM (N=2; *p<0.05)
Fig. 4 Viability of HIPEC 65 cells as measured by WST-1 assay. Cells
were exposed to 10 μM MTX and/or 100 nM PACAP1-38, as indicated
in the figure. ***p<0.001 compared to control group
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503 Since placental oxygenation is an important factor in control-
504 ling angiogenic factor production, these data suggest that
505 PACAP1-38 may play an important role in the fine regulation
506 of angiogenesis by modulating the production of different
507 angiogenic factors. However, regulation of these factors by
508 PACAP1-38 in hypoxic conditions merit further investigation.
509 The immune microenvironment of the fetomaternal inter-
510 face is crucial for the maintenance of pregnancy, and cyto-
511 kines are considered to be key regulators. For many years,
512 Th1/Th2 hypothesis has provided a useful framework for
513 studies of the immunology of pregnancy. However, the find-
514 ings that pregnancy itself is an inflammatory state have led to a
515 revision of this hypothesis and now it is apparent that both
516 arms of the immune response are intensified during healthy
517 pregnancy, but with a stronger bias towards Th2 than Th1
518 responses. This Th2 cytokine polarization occurs both at
519systemic level and at the fetal–maternal interface and the
520cause behind this cytokine shift are not clearly defined.
521Based on the well-known immunomodulatory actions of
522the VIP–PACAP peptide family (Ganea and Delgado 2002),
523we proposed that PACAP would be involved in cytokine
524production of decidual cells. Recently, VIP has been shown
525to be involved in recruitment of T cells during the
526decidualization process (Grasso et al. 2014). In this study,
527we analyzed the effect of PACAP1-38 and PACAP6-38 on
528the inflammatory and proinflammatory cytokine production
529of peripheral and decidual lymphocytes obtained from healthy
530pregnant women. Investigating Th1 and Th2 cytokine pro-
531duction by peripheral and decidual cells, we did not find any
532characteristic differences after PACAP1-38 or PACAP6-38
533treatment compared to the control group. These results sug-
534gest that during healthy pregnancy neither in the periphery nor
535at the fetomaternal interface PACAP1-38 or PACAP6-38 reg-
536ulates immune microenvironment by modulating cytokine
537production. Although PACAP has been described to modulate
538cytokine production in several experimental paradigms both
539in vitro and in vivo (Banki et al. 2013; Csanaky et al. 2014;
540Nakamachi et al. 2012), it seems that PACAP does not have
541such an effect on decidual lymphocytes, which further sup-
542ports the finding that the actions of PACAP are dependent on
543cell types and several other factors such as cycle, hormonal
544status, and growth factors present in the microenvironment
545(Vaudry et al. 2009; Szabo et al. 2004; Somogyvari-Vigh and
546Reglodi 2004).
547Based on our results, PACAP has different effects on
548different placental cells. This differential effect may be the
549result of the nature of the cells (normal, tumorous or chal-
550lenged) or other causes of the different functions can be the
551expression of different receptorial splice variants as well as the
Fig. 5 EQ5 ffect of MTX and PACAP1-38 on cell survival in HIPEC 65
trophoblast cells. Distinction between living, necrotic, early, and late
apoptotic cells. Examples of dot plots (a) as determined by flow cytom-
etry following annexin V and propidium iodide double staining. Hori-
zontal axis represents annexin V intensity and vertical axis shows PI
staining. The lines divide each plot into quadrants—lower left quadrant
living cells (AnV−/PI−), lower right quadrant early apoptotic cells
(AnV+/PI−), upper left quadrant necrotic cells (AnV−/PI+), upper right
quadrant late apoptotic cells (AnV+/PI+). Graphs (b) demonstrate the
mean percentage of living cells, ratio of cells in early and late apoptosis.
*p<0.05, **p<0.01
Fig. 6 Invasion and proliferation of HIPEC 65 cells as assessed by
invasion assay based on Boyden chamber principle. Cells were treated
with PACAP1-38. *p<0.05 compared to control group
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Fig. 7 Secreted angiogenic factors by peripheral blood and decidual
mononuclear cells. a Angiogenesis array with cell-conditioned media of
untreated or 1 μM PACAP1-38 treated (24 h) peripheral blood
mononuclear cells. b Angiogenesis array with cell-conditioned media of
untreated or 1 μMPACAP1-38 treated (24 h) decidual mononuclear cells
t1:1 Table 1 Cytokine production by
decidual and peripheral blood
mononuclear cells in healthy
pregnant women
t1:2 pg/ml Control +PACAP1-38 +PACAP1-38+
PACAP6-38
+PACAP36-38
t1:3 PBMC IL-2 734.7 742.7 755.9 753.3
t1:4 IL-4 88.7 88.7 86.3 88.7
t1:5 IL-6 76.8 78.5 78.5 81.6
t1:6 IL-10 262.3 250 260.3 266.4
t1:7 TNF-α 1,016.1 1,017.9 1,068.4 1,064.8
t1:8 IFN-γ 653 644.3 729.4 665.1
t1:9 Decidual
lymphocytes
IL-2 562.8 563.6 575.3 577.8
t1:10 IL-4 25.9 25.9 29.3 29.3
t1:11 IL-6 99.5 96.5 95 99.5
t1:12 IL-10 184.5 160 160 164.1
t1:13 TNF-α 814.1 767.2 783.4 823.1
t1:14 IFN-γ 408.9 424.7 408.9 424.7
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552 temporal and spatial distribution of the PACAP receptors in
553 the placenta. The expression of the different PACAP receptors
554 in the various placental cell types is not fully characterized yet.
555 The expression of PAC1 and VPAC receptors has been shown
556 in the placenta. The gene encoding VPAC receptors is weakly
557 expressed in the human placenta (Sreedharan et al. 1995). In
558 human placental tissues, Scaldaferri et al. (2000) found ex-
559 pression of the variants PAC1SV1 and SV2. Radioligand
560 binding studies have confirmed that PACAP is able to bind
561 to placental tissues (Scaldaferri et al. 2000). Koh et al. de-
562 scribed that the expression of PAC1 receptors shows temporal
563 and spatial variance—PAC1 receptor mRNA expression in-
564 creases with the progression of pregnancy and varies between
565 d i f f e r en t c e l l t y p e s and cy t o t r ophob l a s t a nd
566 syncytiotrophoblast cells show weaker expression than decid-
567 ual cells or chorionic vessels (Koh et al. 2005). Furthermore, a
568 great interspecies difference also exists between rats and
569 humans (Koh et al. 2003, 2005; Scaldaferri et al. 2000). A
570 detailed mapping of the changes in receptor expression and
571 their splice variants would be necessary to exactly verify the
572 different effects of PACAP in the placenta throughout the
573 entire pregnancy.
574 Our present results indicate that PACAP has some effects
575 on mechanisms playing a role in invasiveness and implanta-
576 tion in certain cell types, while it has no effects on others. Our
577 results could be a starting point to further investigation on the
578 influence of PACAP on trophoblast cells.
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